Cardiometabolic and Organ System Monitoring

Blood Pressure and Weight

Hypertension is the most common diabetes comorbidity and a major driver of both macrovascular and microvascular complications. ADA Standards of Care recommend blood pressure be measured at every routine clinical visit, at minimum every 6 months, using proper technique — seated, back supported, feet flat, arm at heart level, after 5 minutes of rest. Home blood pressure monitoring is encouraged to confirm office readings and detect white-coat or masked hypertension. Hypertension is diagnosed at a confirmed average of 130/80 mmHg or higher across two or more readings on two or more separate occasions; a reading of 120-129 systolic with diastolic under 80 (elevated, not yet diagnostic) should prompt repeat confirmation rather than an immediate diagnosis.

Weight and BMI should be assessed at every visit — weight trends inform medication selection (many GLP-1- and GIP-based therapies are weight-favorable, while some sulfonylureas and thiazolidinediones promote weight gain), flag unintentional weight loss (a red flag for uncontrolled hyperglycemia or an alternate diagnosis), and track progress toward individualized weight goals.

Lipid Monitoring

A lipid panel should be obtained at diabetes diagnosis, at the initial comprehensive medical evaluation, and at minimum every 5 years thereafter in adults under 40 not on lipid-lowering therapy; more frequent panels are reasonable in younger people with long diabetes duration, such as youth-onset type 1 diabetes, or in anyone with worsening cardiovascular risk. Once statin therapy starts, LDL cholesterol should be rechecked 4-12 weeks after initiation or any dose change, then annually to monitor adherence and response.

Kidney Monitoring

Diabetic kidney disease is screened with two complementary tests that must both be obtained: estimated glomerular filtration rate (eGFR), calculated from serum creatinine, and urine albumin-to-creatinine ratio (UACR), a spot urine sample. Both should be measured at least annually — starting at diagnosis for type 2 diabetes and beginning 5 years after diagnosis for type 1 diabetes. Once chronic kidney disease (CKD) is identified, monitoring frequency increases to 1-4 times per year depending on CKD stage and severity, which guides nephrology referral timing and medication adjustments such as renally-cleared drug dosing and cardiorenal-protective agent selection (Chapter 8).

Hepatic Monitoring

Because metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) affects a majority of people with type 2 diabetes, ADA now recommends screening all adults with type 2 diabetes or prediabetes for liver fibrosis regardless of liver enzyme levels — normal ALT and AST do not rule out significant fibrosis. The first-line tool is the FIB-4 index, calculated from age, AST, ALT, and platelet count. A low-risk FIB-4 score allows primary-care management with rescreening roughly every 1-3 years; a FIB-4 score at or above the risk threshold triggers a second-line test — liver stiffness measurement by vibration-controlled transient elastography (VCTE), or the Enhanced Liver Fibrosis (ELF) test — to determine whether hepatology referral is warranted.

The FIB-4 index is calculated as (age × AST) ÷ (platelet count × √ALT), producing a score that stratifies fibrosis risk: below 1.30 (below 2.0 in adults 65 and older) is low risk, 1.30-2.67 (2.0-2.67 if 65 or older) is indeterminate, and above 2.67 is high risk. The CDCES does not calculate FIB-4 independently but should recognize the score on a lab report or patient portal and know that an indeterminate or high-risk result routes the person to further testing or hepatology referral rather than reassurance.

Home Monitoring Between Visits

Home monitoring extends the clinic schedule between visits. A validated, properly sized home blood pressure cuff — arm circumference matters, since an undersized cuff falsely elevates readings — lets the person track trends and bring several weeks of home readings to each visit. Home scales support weight-trend tracking between annual labs. The CDCES teaches correct home BP technique (same arm, same time of day, seated and rested after 5 minutes) and reinforces that home readings supplement, rather than replace, the clinic and laboratory schedule described above.

The CDCES Role Across These Metrics

No monitoring result exists in isolation. The CDCES integrates blood pressure, weight, lipid, kidney, and hepatic trends into the same person-centered education plan used for glycemic metrics (Chapter 5): explaining why each test matters, what an abnormal result means for daily self-care, and how results connect to medication selection (Chapter 8) and complication risk reduction (Chapter 11). Missed or overdue monitoring is itself a self-management barrier worth assessing (Chapter 4) — cost, transportation, and health literacy are common reasons people fall out of the recommended monitoring cadence.